Abstract
Results of the PARAMETER study demonstrated that the angiotensin receptor neprilysin inhibitor LCZ696 reduced central aortic systolic and pulse pressure more effectively than olmesartan in older patients with systolic hypertension and arterial stiffness. Both treatments were safe and well tolerated without significantly variability in key safety parameters between the groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.